Front. Pharmacol.
Frontiers in Pharmacology
Front. Pharmacol.
1663-9812
Frontiers Media S.A.
758130
10.3389/fphar.2021.758130
Pharmacology
Erratum
Erratum: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Frontiers Production Office
Erratum: Mcl-1 in Multiple Myeloma
Frontiers Production Office
*
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Frontiers Production Office, pharmacology.production.office@frontiersin.org
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
31
08
2021
2021
12
758130
13
08
2021
13
08
2021
Copyright © 2021 Frontiers Production Office.
2021
Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
An Erratum onMcl-1 Inhibition: Managing Malignancy in Multiple Myeloma by Al-Odat, O. S., von Suskil, M., Chitren, R. J., Elbezanti, W. O., Srivastava, S. K., Budak-Alpddogan, T., Jonnalagadda, S. C., Aggarwal, B. B., and Pandey, M. K. (2021) Front. Pharmacol. 12:699629. doi: 10.3389/fphar.2021.699629
multiple myeloma
drug resistant
Mcl-1
Bcl-2 homology 3 mimetics
apoptosis
Due to a production error, several author names were incorrectly written. The names of Omar S. Al-Odat, Robert J. Chitren, Weam O. Elbezanti, Sandeep K. Srivastava, Subash C. Jonnalagadda, and Bharat B. Aggarwal had their initials mistakenly omitted.
The publisher apologizes for this mistake.